Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer ...

Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR ...

The company reported strong efficacy and a clean safety profile from its ongoing Phase 2 Advanced-2 bladder cancer trial. ・Durability signals were notable, with 68% of BCG-unresponsive patients and 66 ...

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Relmada Therapeutics, Inc. is one of them. Relmada Therapeutics, Inc. (NASDAQ:RLMD) is a clinical-stage biotechnology ...

Aura Biosciences (NASDAQ:AURA) highlighted progress across its ocular oncology pipeline and provided updates on a parallel effort in bladder cancer during a fireside chat at TD Cowen’s 46th Annual ...

RAANANA, Israel (Reuters) - Israel's UroGen Pharma plans to begin a mid-stage trial of its treatment for bladder cancer patients in August, after positive interim results last month from an advanced ...

Overall survival appears no worse for patients with organ-confined limited-stage small cell bladder cancer receiving multimodal organ-preserving treatment. For patients with limited-stage small-cell ...